Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: HemaSure

This article was originally published in The Gray Sheet

Executive Summary

HemaSure: President Steven Rouhandeh gains additional posts of chief executive officer and director effective Dec. 12. Rouhandeh succeeds Eugene Zurlo, who will remain as chairman of the board. HemaSure also announces that Edward Kelly, currently its president-medical devices, will assume the newly created titles of executive vice president and chief operating officer. Marlborough, Massachusetts-based HemaSure is in clinical trials for its SteriPath blood pathogen inactivation system; its LeukoNet Filter for leukocyte removal was 510(k) cleared in June of 1995...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT007267

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel